The Immunoscore has been internationally validated in colorectal cancer[1] and provides better prognostic information than the current staging system, TNM.
It is based on Jerome Galon's finding from 2006[2] which revealed a positive association of cytotoxic and memory T cells with survival of colorectal cancer patients.
From the beginning of 21st century, growing evidences supports the important role of the immune system in cancer surveillance and clearance.
[4] Immunoscore incorporates the effects of the host immune response into cancer classification and improves prognostic accuracy.
[5] The Immunoscore does not measure how the immune cells in the periphery of the tumor are organized, or the amount of B-cells, tertiary lymphoid structures and germinal centers.